Research Study

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Principal Investigator 
Heather J. Sutherland

Overview

Body Locations and Systems 
Blood
Disorders and Conditions 
Multiple Myeloma
ClinicalTrials.gov# 
NCT02076009
Status 
Closed to Recruitment
Study Start/End 
Oct 3, 2014 to Dec 31, 2019
Locations 
Vancouver General Hospital
Name/Title 
Tania Haqq, Clinical Trials Research Associate
Phone 
604-875-4111 ext.67409
Email Address 
thaqq@bccancer.bc.ca
Purpose of Study 

The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.